Skip to main content
. Author manuscript; available in PMC: 2021 Nov 1.
Published in final edited form as: Biol Blood Marrow Transplant. 2020 Jul 25;26(11):2147–2154. doi: 10.1016/j.bbmt.2020.07.024

Table 6.

CMV antigenemia primes CASTs to prevent subsequent CMV reactivation

A. In R+D± patients with a maximum of grade II acute GvHD, reactivating CMV and achieving ≥3 CASTs/μL by day+100 is associated with decreased CMV reactivation from day+100 to +365. The chronologic pattern of CMV reactivation and CASTs reconstitution for the individual subjects in this table are shown in Supplemental Figure 6.
CMV reactivation
between day+100
and +365		 Blood concentration of CASTs by day+100 p-value
<3/μL
(N=13)
N (%)		 ≥3/uL
(N=30)
N (%)
No 5 (38) 22 (73) 0.04
Yes 8 (62) 8 (27)
B. In R+D± patients with a maximum of grade II acute GvHD, developing low level CMV antigenemia (<5/50,000 PMNs+pp65) and achieving ≥3 CASTs/μL by day+100 is associated with decreased CMV reactivation from day+100 to +365.
CMV reactivation
between day+100
and +365		 Blood concentration of CASTs by day+100 p-value
<3/μL
(N=10)
N (%)		 ≥3/μL
(N=18)
N (%)
No 3 (30) 13 (76) 0.04
Yes 7 (70) 4 (24)

Abbreviations: CAST – CMV antigen specific T cell, CMV – cytomegalovirus, GvHD – graft versus host disease, D – donor CMV serotype, N – number, NS – not significant, PMNs+pp65 – polymorphonuclear cells positive for pp65 antigen, R – recipient CMV serotype.